Table 3. Overall efficacy results in the triweekly, weekly, and sorafenib-resistant cohorts.
| Triweekly cohort (n=27) | Weekly cohort (n=13) | Sorafenib resistant (n=12) | |
|---|---|---|---|
| Best response at any time, n (%) | |||
| CR | 1 (4) | — | 1 (8) |
| PR | 1 (4) | — | — |
| Response rate (CR+PR) | 2 (7) | — | 1 (8) |
| SD | 6 (22) | 5 (38) | 3 (25) |
| Disease control rate (CR+PR+SD) | 8 (30) | 5 (38) | 4 (33) |
| PD | 17 (62) | 8 (62) | 8 (67) |
| Non-assessable* | 2 (8) | — | — |
| PFS in all patients (months) | |||
| Median (95% CI) | 2.3 (1.7–2.9) | 2.0 (1.7–2.9) | 2.1 (1.8–2.4) |
| PFS in patients with disease control | |||
| Median (95% CI) | 4.3 (1.2–6.7) | 3.6 (0.0–7.4) | 4.3 (1.3–6.7) |
| OS (months) | |||
| Median (95% CI) | 8.9 (7.5–10.2) | NR (—) | 9.5 (3.3–15.7) |
Abbreviations: CI=confidence interval; CR=complete response; NR=not reached; OS=overall survival; PD=progressive disease; PFS=progression-free survival; PR=partial response; SD=stable disease. *Two patients were withdrawn from the study before their first restaging because of symptonatic deterioration.